Carcinoid Syndrome Trends And Growth Diarrhea Treatment Market Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction. If remained undiagnosed, it could lead to several complications such as weight loss, electrolyte imbalance, dehydrations, menopause, irritable bowel disease, and asthma. For instance, in 2009, a study by Journal of Clinical Oncology, showed 4 to 5 out of every 100,000 people are diagnosed with a neuroendocrine tumor and over 100,000 people suffering from neuroendocrine tumor in the U.S., also most individual suffering from carcinoid are asymptomatic until the tumor is fully developed. To overcome the carcinoid crisis, treatment options may considered such as surgery, chemotherapy, targeted radionuclide therapy, radiofrequency ablation, and chemoembolization on the basis of patient-by-patient. Carcinoid syndrome being a rare condition, there are very few if any treatment options available. This in turn, creates a highly lucrative opportunities for market players. ๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ ๐๐ซ๐จ๐๐ก๐ฎ๐ซ๐ ๐๐ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐๐ฉ๐จ๐ซ๐ญ : https://www.coherentmarketinsights.com/insight/request-pdf/1216 Report includes chapters which deeply display the following deliverable about industry : โข Carcinoid Syndrome Diarrhea Treatment Market Research Objective and Assumption โข Carcinoid Syndrome Diarrhea Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) โข Carcinoid Syndrome Diarrhea Treatment Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porterโs Analysis, and PEST Analysis โข Global Carcinoid Syndrome Diarrhea Treatment Market, By Regions โข Carcinoid Syndrome Diarrhea Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. โข Carcinoid Syndrome Diarrhea Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. โข Carcinoid Syndrome Diarrhea Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. โข Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers โข Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. โข Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. โข Carcinoid Syndrome Diarrhea Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. โข Research Findings and Conclusion ๐๐ฅ๐จ๐๐๐ฅ ๐๐๐ซ๐๐ข๐ง๐จ๐ข๐ ๐๐ฒ๐ง๐๐ซ๐จ๐ฆ๐ ๐๐ข๐๐ซ๐ซ๐ก๐๐ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฑ๐จ๐ง๐จ๐ฆ๐ฒ : By Treatment Type: โข Chemotherapy โข Oral Therapy โข Somatostatin Analog (SSA) Therapy By Distribution Channel: โข Hospital Pharmacies โข Retail Pharmacies โข Online Pharmacies ๐๐จ๐ฏ๐๐ฅ ๐ ๐ซ๐จ๐ฎ๐ง๐-๐๐ซ๐๐๐ค๐ข๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ฒ ๐ญ๐จ ๐ฉ๐ซ๐จ๐ฏ๐ข๐๐ ๐ข๐ฆ๐ฆ๐๐ง๐ฌ๐ ๐จ๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ ๐๐จ๐ซ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ ๐ซ๐จ๐ฐ๐ญ๐ก In February 2017, Lexicon Pharmaceutical Inc., announced that the U.S. Food and Drug Administration (FDA) approved Xermelo (Telotristat etiprate) as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy (SSA) for adults. Xermelo mainly targets the overproduction of serotonin hormone inside mNET cells and reduces the frequency of carcinoid syndrome diarrhea. Furthermore, in 2017, Ipsen Biopharmaceutical, announced the U.S. Food and Drug Administration (FDA) approval for a supplemental indication of Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome, to reduce the frequency of shortacting somatostatin analogue rescue therapy. Development of first-of-its-kind therapeutic approach to treat carcinoid syndrome diarrhea creates highly lucrative growth opportunities for market players. However, low awareness and certain side effects associated with this therapy are expected to hinder growth of the carcinoid syndrome diarrhea treatment market. ๐๐ง๐๐ซ๐๐๐ฌ๐ข๐ง๐ ๐ฉ๐ซ๐๐ฏ๐๐ฅ๐๐ง๐๐ ๐จ๐ ๐ซ๐๐ซ๐ ๐๐๐ซ๐๐ข๐ง๐จ๐ข๐ ๐ฌ๐ฒ๐ง๐๐ซ๐จ๐ฆ๐ ๐๐ข๐๐ซ๐ซ๐ก๐๐ ๐ญ๐จ ๐๐จ๐จ๐ฌ๐ญ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ ๐ซ๐จ๐ฐ๐ญ๐ก According to the National Organization for Rare Disorders (NORD), 2017, each year, only 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U.S., amongst whom, only 10% individuals develop carcinoid syndrome. Moreover, it affects both males and females in equal number. Increasing prevalence of the disease is in turn, increasing demand for carcinoid syndrome diarrhea treatment devices. This in turn is expected to fuel growth of the carcinoid syndrome diarrhea treatment market. ๐๐ซ๐จ๐ฐ๐ฌ๐ ๐๐จ๐ฆ๐ฉ๐ฅ๐๐ญ๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ ๐จ๐ซ ๐๐จ๐ซ๐ ๐๐ง๐๐จ๐ซ๐ฆ๐๐ญ๐ข๐จ๐ง @ https://www.coherentmarketinsights.com/ongoing-insight/carcinoid-syndrome-diarrhea-treatmentmarket-1216 ๐๐๐ฃ๐จ๐ซ ๐ค๐๐ฒ ๐ฉ๐ฅ๐๐ฒ๐๐ซ๐ฌ ๐จ๐ฉ๐๐ซ๐๐ญ๐ข๐ง๐ ๐ข๐ง ๐ญ๐ก๐ ๐๐๐ซ๐๐ข๐ง๐จ๐ข๐ ๐ฌ๐ฒ๐ง๐๐ซ๐จ๐ฆ๐ ๐๐ข๐๐ซ๐ซ๐ก๐๐ ๐ญ๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ข๐ง๐๐ฅ๐ฎ๐๐ ๐๐๐ฑ๐ข๐๐จ๐ง ๐๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ๐ฌ, ๐๐ง๐., ๐๐จ๐ฏ๐๐ซ๐ญ๐ข๐ฌ ๐๐ง๐ญ๐๐ซ๐ง๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐ (๐๐๐ง๐๐จ ), ๐๐ก๐๐ซ๐ฆ๐๐ฌ๐๐ข๐๐ง๐๐ ๐๐ง๐ ., ๐๐ฆ๐๐ ๐ ๐๐๐๐จ๐ซ๐๐ญ๐จ๐ซ๐ข๐๐ฌ ๐๐ญ๐., ๐๐๐ฏ๐ ๐๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ข๐๐ฌ ๐๐ญ๐ ., ๐๐ฒ๐ฅ๐๐ง ๐.% ., ๐๐ฉ๐ฌ๐๐ง ๐๐ข๐จ๐ฉ๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ๐ฌ , ๐๐ง๐., ๐๐ข๐ซ๐ญ๐๐ฑ ๐๐๐๐ข๐๐๐ฅ ๐๐ข๐ฆ๐ข๐ญ๐๐, ๐๐ง๐ ๐๐ ๐๐ง๐ญ๐๐ซ๐ง๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐ญ๐. ๐๐๐จ๐ฎ๐ญ ๐๐จ๐ก๐๐ซ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. ๐๐จ๐ง๐ญ๐๐๐ญ ๐๐ฌ Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 ๐๐ฆ๐๐ข๐ฅ: sales@coherentmarketinsights.com
Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors.
© Copyright 2024 Paperzz
